Get the Stockscreener App
0.8101
2.44%
0.0193
Palatin Technologies Inc. stock is traded at $0.8101, with a volume of 364.67K.
It is up +2.44% in the last 24 hours and down -18.99% over the past month.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
See More
Previous Close:
$0.7908
Open:
$0.8546
24h Volume:
364.67K
Relative Volume:
0.44
Market Cap:
$21.07M
Revenue:
$7.10M
Net Income/Loss:
$-31.59M
P/E Ratio:
-0.3104
EPS:
-2.61
Net Cash Flow:
$-26.75M
1W Performance:
+4.87%
1M Performance:
-18.99%
6M Performance:
-40.87%
1Y Performance:
-47.40%
1-Day Range:
$0.7614
$0.871
1-Week Range:
$0.7299
$0.871
52-Week Range:
$0.68
$2.88
Palatin Technologies Inc. Stock (PTN) Company Profile
Name
Palatin Technologies Inc.
Sector
Industry
Phone
609-495-2200
Address
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.8101 | 21.07M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
513.76 | 131.93B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.42 | 74.17B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.19 | 37.32B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.11 | 32.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
265.07 | 28.49B | 3.32B | -860.46M | -1.04B | -8.32 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-15 | Reiterated | Canaccord Genuity | Buy |
| Jan-12-15 | Reiterated | ROTH Capital | Buy |
| May-23-12 | Initiated | Noble Financial | Buy |
| Jan-23-07 | Initiated | Next Generation | Buy |
Palatin Technologies Inc. Stock (PTN) Latest News
Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Palatin Technologies (NYSEAMERICAN:PTN) Shares Pass Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus.com
Palatin gears up for obesity treatment trials in 2025 - MSN
Palatin Awaits Data Release From Phase 2 Trial Of Bremelanotide-Tirzepatide Combo In Weight Loss - RTTNews
Palatin secures $4.7 million in stock and warrant sale By Investing.com - Investing.com Nigeria
HC Wainwright Cuts Palatin Technologies (NYSEAMERICAN:PTN) Price Target to $7.00 - Armenian Reporter
HC Wainwright Issues Pessimistic Forecast for Palatin Technologies (NYSEAMERICAN:PTN) Stock Price - Defense World
Palatin Technologies, Inc. (AMEX:PTN) Q2 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Reports Q2 2025 Financial Results - TipRanks
Earnings call transcript: Palatin Technologies Q2 FY2025 sees stock surge By Investing.com - Investing.com Nigeria
Palatin’s Earnings Call: Mixed Results and Strategic Moves - TipRanks
Earnings call transcript: Palatin Technologies Q2 FY2025 sees stock surge - Investing.com
Palatin Technologies Q2 25 Earnings Conference Call At 11:00 AM ET - Nasdaq
Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates - Nasdaq
Palatin Slashes Quarterly Losses 70%, Obesity Drug Trial Results Imminent - StockTitan
Palatin secures $4.7 million in stock and warrant sale - MSN
Palatin Technologies (PTN) Expected to Post Earnings on Wednesday - Defense World
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025 - BioSpace
Palatin (PTN) Q2 Earnings: Strategic Update & Pipeline ProgressKey Details Coming Feb 13 - StockTitan
A closer look at PTN’s price-to-free cash flow ratio - US Post News
Palatin Technologies’ (PTN) Buy Rating Reiterated at HC Wainwright - Defense World
A Look at Palatin Technologies Inc (PTN) Shares in the Recent Past Indicates Growth - SETE News
Data la crescita esponenziale del settore del turismo in Arabia Saudita, dmg events annuncia il salone Hotel & Hospitality Expo - GlobeNewswire Inc.
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement - Nasdaq
PTNPalatin Tech Latest Stock News & Market Updates - StockTitan
Palatin Technologies Inc [PTN] stock for 8,274 USD was sold by WILLS STEPHEN T - Knox Daily
Palatin Gains on New Offering - Baystreet.ca
Palatin Technologies prices 4.69M shares in direct offering - MSN
Palatin Announces $4.7 Million Registered Direct Offering and Co - GuruFocus.com
Palatin Technologies Announces $4.7 Mln Direct Offering - Nasdaq
Palatin concludes Phase II trial of combination therapy for obesity - Yahoo Finance
Palatin finishes phase 2 trial in obesity treatment study By Investing.com - Investing.com Nigeria
Palatin finishes phase 2 trial in obesity treatment study - MSN
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide - GuruFocus.com
PTN’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Palatin Technologies Inc (PTN) Stock: What the Analysts are Saying - The News Heater
PTN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Market Watch: Palatin Technologies Inc (PTN)’s Noteworthy Drop, Closing at 0.80 - The Dwinnex
Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World
Palatin gears up for obesity treatment trials in 2025 By Investing.com - Investing.com Canada
Palatin Technologies Inc. Stock (PTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
3.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):